MDT

86.12

+0.38%↑

121.33

+2.77%↑

VEEV

167.59

+1.04%↑

HQY

85.7

+1.56%↑

NEOG

9.53

+3.03%↑

MDT

86.12

+0.38%↑

121.33

+2.77%↑

VEEV

167.59

+1.04%↑

HQY

85.7

+1.56%↑

NEOG

9.53

+3.03%↑

MDT

86.12

+0.38%↑

121.33

+2.77%↑

VEEV

167.59

+1.04%↑

HQY

85.7

+1.56%↑

NEOG

9.53

+3.03%↑

MDT

86.12

+0.38%↑

121.33

+2.77%↑

VEEV

167.59

+1.04%↑

HQY

85.7

+1.56%↑

NEOG

9.53

+3.03%↑

MDT

86.12

+0.38%↑

121.33

+2.77%↑

VEEV

167.59

+1.04%↑

HQY

85.7

+1.56%↑

NEOG

9.53

+3.03%↑

Home・Akcijų sąrašas・Erasca Inc

Erasca Inc

Atidarymo kaina

19.03 5.96

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

18.22

Max

19.6

Pagrindiniai rodikliai
By Trading Economics
Pajamos	1.5M -29M
Darbuotojai	103
EBITDA	-2M -32M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	-6.1% downside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-11

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	190M 5.1B
Ankstesnė atidarymo kaina	13.07
Ankstesnė uždarymo kaina	19.03

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bearish Evidence

1.39 / 1.44 Palaikymas ir pasipriešinimas

Erasca Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-16 23:26; UTC

Karštos akcijos

Stocks to Watch: Netflix, Alcoa, Knight-Swift, NiSource

2026-04-16 20:41; UTC

Pagrindinės rinkos jėgos

Netflix Shares Slide After 2Q Outlook Misses Wall Street's Expectations

2026-04-16 23:49; UTC

Rinkos pokalbiai

Amplitude's Pivot to Oil-Linked Supply Deal Catches Bull's Eye -- Market Talk

2026-04-16 23:45; UTC

Rinkos pokalbiai

Nikkei May Decline After Hitting Record High -- Market Talk

2026-04-16 23:33; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Gold Edges Higher on Hopes for U.S.-Iran Deal -- Market Talk

2026-04-16 22:51; UTC

Rinkos pokalbiai

Netflix Sees Signs That Podcasts May Boost Engagement -- Market Talk

2026-04-16 22:08; UTC

Uždarbis

Netflix Chair Reed Hastings to Leave Board in June -- 3rd Update

2026-04-16 22:06; UTC

Uždarbis

Lundin Mining: Earnings From Discontinued Ops in 1Q Expected to Be Positively Impacted by Unaudited Gain on Disposal of Eagle Mine, Totaling Approximately $4M >LUN.T

2026-04-16 22:06; UTC

Uždarbis

Lundin Mining: Pre-Announces Items Impacting 1Q Results

2026-04-16 22:06; UTC

Uždarbis

Lundin Mining: Items of Significant Impact in 1Q Expected to Include Unaudited Realized Losses on Derivative Contracts of Approximately $13M, Primarily Related to Gold Collar Contracts >LUN.T

2026-04-16 22:06; UTC

Uždarbis

Lundin Mining: Rev in 1Q Expected to Be Positively Impacted by Unaudited Provisional Pricing Adjustments on Prior-Period Concentrate Sales of Approximately $22M on Pre-Tax Basis >LUN.T

2026-04-16 22:06; UTC

Uždarbis

Lundin Mining: Adjustments Primarily Include Upward Adjustments in Relation to Prior-Period Metal Sales >LUN.T

2026-04-16 20:50; UTC

Rinkos pokalbiai

Uždarbis

Tech, Media & Telecom Roundup: Market Talk

2026-04-16 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-04-16 20:50; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Basic Materials Roundup: Market Talk

2026-04-16 20:50; UTC

Rinkos pokalbiai

Uždarbis

Health Care Roundup: Market Talk

2026-04-16 20:49; UTC

Uždarbis

SpaceX Is Ready to Go Public. The Stock Market Is Its Rocket. -- Barrons.com

2026-04-16 20:43; UTC

Uždarbis

Update: Netflix Stock Falls on Weak Guidance. Founder Reed Hastings Is Leaving the Board. -- Barrons.com

2026-04-16 20:40; UTC

Rinkos pokalbiai

Uždarbis

Global Equities Roundup: Market Talk

2026-04-16 20:40; UTC

Rinkos pokalbiai

Uždarbis

Netflix Says Engagement Quality Hits New High -- Market Talk

2026-04-16 20:30; UTC

Karštos akcijos

Stocks to Watch: TSMC, Abbott Laboratories, Nvidia, Netflix -- WSJ

2026-04-16 20:25; UTC

Uždarbis

Netflix Stock Falls on Weak Guidance. Founder Reed Hastings Is Leaving the Board. -- Barrons.com

2026-04-16 20:23; UTC

Uždarbis

These Stocks Are Today's Movers: AMD, Intel, TSMC, Abbott, Hims, Corning, Schwab, Polaris, and More -- Barrons.com

2026-04-16 20:19; UTC

Uždarbis

Netflix Guidance Disappoints. The Stock Is Down. -- Barrons.com

2026-04-16 20:17; UTC

Uždarbis

Alcoa: Alumina Costs in the Aluminum Segment Are Expected to Be Favorable by Approximately $20M Sequentially >AA

2026-04-16 20:17; UTC

Uždarbis

Alcoa: Based on Higher LME and Midwest Premium Pricing and Expected Higher Shipments, Section 232 Tariff Costs on U.S. Imports of Aluminum From Canada Expected to Increase $35M Sequentially >AA

2026-04-16 20:16; UTC

Uždarbis

Alcoa: Expects 2026 Total Aluminum Segment Production and Shipments Ranging Between 2.4M and 2.6M Metric Tons, and Between 2.6M and 2.8M Metric Tons, Respectively >AA

2026-04-16 20:16; UTC

Uždarbis

Alcoa: Expects 2026 Total Aluminum Segment Production and Shipments to Remain Unchanged From Its Prior Projection >AA

2026-04-16 20:16; UTC

Uždarbis

Alcoa: Expects 2026 Total Alumina Segment Production and Shipments Ranging Between 9.7M to 9.9M Metric Tons, and Between 11.8M and 12.0M Metric Tons, Respectively >AA

2026-04-16 20:16; UTC

Uždarbis

Alcoa: Expects 2026 Total Alumina Segment Production and Shipments to Remain Unchanged From Prior Projection >AA

Akcijų palyginimas

Kainos pokytis

Erasca Inc Prognozė

Kainos tikslas

By TipRanks

-6.1% į apačią

12 mėnesių prognozė

Vidutinis 17.09 USD -6.1%

Aukščiausias 25 USD

Žemiausias 2 USD

Remiantis 11 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Erasca Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

11 ratings

Pirkti

Laikyti

Parduoti

Remiantis 11 analitikų, pateikusių Erasca Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

1.39 / 1.44Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Erasca Inc

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.